

O

13.06.2016. , 5940/5,
:

"

"

. . .

:

1. . ,
2. . ,
3. . ,

,

)

161

: , ,

,
21

, 11 , 35 .

()

a

2 1

16 18

1 2
1

6, 7 5.

16 6/ 7

1 1
1, 1,

2011. 2015.

” “ - ” “

50,2 ± 11,40

(*engl.* World Health Organisation),
FIGO

5-10

5-10 µm,

(QIAGEN, USA).

(*engl.* Polymerase Chain Reaction-PCR)

E1, L1
MY09/11

16 6/ 7

1

L1
GP1/GP2

(E1, L1 E6/ 7)

PCR

QIAGEN MinElute PCR Purification Kita (QIAGEN, USA),

(*engl.* "forward" i "reverse")
Sequencing kit (Applied Biosystems, SAD).

Big Dye Terminator v3.1 Cycle

75%

ABI Prism

310 Genetic Analyser system-u (Applied Biosystems, SAD).

(*engl.* "Flow through")

GenoFlow HPV Array Test Kit (DiagCor Bioscience,

Kina).

PCR

GenBank/EMBL/DDBJ

NJ (*engl.* "Neighbor Joining"), ML (*engl.*

"Maximum Likelihood") MP (*engl.* "Maximum Parsimony")
(*bootstrap*) 500

Fisher

(*engl.* , kappa ()

0,05.

e

PCR,

1 L1 ,

135

)

2011-2015,

(),

, 101

101

, 91

(90,09%),

10

(9,91%).

, 35

, 56

10

PCR

E1 i L1
450bp 57 (56,43%) 101

PCR E1

350bp i 550bp.
450bp 35 (34,65%) 101

L1

L1

23

L1

PCR

1 L1 69 101 (68,31%).

69

44 1 9 L1

1 L1

1 L1

GenBank

1

PCR

44 57

1

16, 33, 45 58.

16 (81,81%), 33 (9,09%), 58 45

29,54%

PCR 1

16.

L1 9 35

PCR 16, 18

53. L1

16 (20,0%), 18 53

26 (74,28%)

: 16, 33, 58, 45, 18 53,

47

1 L1 ,

PCR

13

1 ,
PCR

7 (35,0%)

20

(16, 18, 59)

(71).

(57,14%)

4 7

59,

71 18
PCR

16,

1 PCR

(16, 59, 18, 71)

16,

101

59,

),

(49

18, 33, 45, 53, 58, 59 71.

: 16,

(79, 59%)

I FIGO

(32 49).

46

3

16

80,43 %

66,7%

(28 49).

16

,
16 6/7 . 44 1 ,9 1 3
1

9 7. 1
0-1%.

1
9,6 7. 1
0-1%.

16 1
1 2
3 4 - ,

16 1
1, 3 4 , - ,
0,5%.

16 6/7
6/7 2 3 , .
1
6 1

/ - .
33 58 1
58 33 1, 2, ,

)

(90,09%)
 (55,44%),

GP1/GP2 E1 MY09/MY11 L1

68,31%

34,65%),

1 1 (56,43%

20

(16, 18, 31 45) -9 (16 31) -7 (18 45)

80%

5, 6, 11.

7 16, 18, 33, 45, 53, 58 59

71.

16 18 58,4% 15,0%,

16 59,6% (30,9% 79,6%) 18 o 16,9%

(0% 44,4%).

31, 33 45,

35, 39, 51, 52, 56, 58, 59 68

16 (80%), 18 3%

33 (6%)

(3,8%), (4,6%) (2,5%),
58 (4%) (3,8%),
(1,1%) (3,5%).

7,7%, 20%. 2
(1,8%). 5
(4,95%)

50,2
40

40 (79,59%)

FIGO

(65,3%).

(89%) (11%).
91,25%.
16 59,3% 36,8%.
18 (36,3%)
36,8%
(80,43% 66,7%), 16 18

0,5 1,0% 1%
 5, 6, 7, 9
 11. 16 9, 18 7.
 16, 18, 33, 58, .),

Alphapapillomavirus 6 (53), 7
 (18 45) 9 (16, 33, 58),

1 1
 0-1% ().

16 (1, 1 6/ 7)
 1, 2, 3 4 0,5%,

33 1
 1, 58 1

)

1. Stamenkovic M, Knezevic A, Kuzmanovic I, Danijela Karalic D, Jovanovic T.
 Distribution of Human Papilloma Virus Genotypes in Cervical Cancer Tissues. Arch. Biol. Sci.2014;66 (2): 563-567.

2. Stamenkovic M, Knezevic A, Knezevic I *i sar.*, High-risk human papilloma virus genotypes in cervical carcinoma of Serbian women:Distribution and association with

pathohistological findings. *Biologicals*. 2016. ,
<http://dx.doi.org/10.1016/j.biologicals.2016.05.001>

) ()

"

"

,

.

,

.

.

.

,

,

.

,

.

,

,

.

, 04.07.2016.

:

:

.

.

.

.
